Last reviewed · How we verify

Systemic Dexamethasone plus perineural bupivacaine

Sherif Mohamed Abd el moneim Soaida, MD · FDA-approved active Small molecule

Systemic dexamethasone reduces inflammation while perineural bupivacaine provides local anesthetic blockade of nerve conduction at the injection site.

Systemic dexamethasone reduces inflammation while perineural bupivacaine provides local anesthetic blockade of nerve conduction at the injection site. Used for Perineural nerve blocks with adjunctive anti-inflammatory effect (specific indication not clearly defined in available literature).

At a glance

Generic nameSystemic Dexamethasone plus perineural bupivacaine
SponsorSherif Mohamed Abd el moneim Soaida, MD
Drug classCombination therapy: corticosteroid + local anesthetic
TargetGlucocorticoid receptor (dexamethasone); voltage-gated sodium channels (bupivacaine)
ModalitySmall molecule
Therapeutic areaPain management / Regional anesthesia
PhaseFDA-approved

Mechanism of action

Dexamethasone is a corticosteroid that suppresses systemic inflammatory responses by inhibiting cytokine production and immune cell activation. Bupivacaine is a local anesthetic that blocks sodium channels in nerve membranes, preventing action potential propagation and pain signal transmission. When combined perineural (around the nerve), this approach aims to provide both local anesthesia and reduce inflammation-mediated nerve injury or pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: